VistaGen Therapeutics (VTGN) Jefferies Global Healthcare Conference summary

Pipeline overview and lead program

• Pipeline includes six clinical-stage assets, five from a novel class called Pherines, with differentiated mechanisms and safety profiles.

• Lead asset, fasedienol, targets social anxiety disorder with rapid onset and no systemic absorption.

• Other assets address major depressive disorder, menopausal hot flashes, psychomotor cognition, and cachexia.

Clinical development and milestones

• Achieved positive phase III results for acute treatment of social anxiety disorder; registration program includes two phase III studies, one already initiated.

• Expect readout of the first new phase III mid-next year, with the second launching in the second half of this year; all studies to read out next year.

• Repeat dose and preclinical studies are planned, with NDA submission targeted for the first half of 2026 if successful.

Market opportunity and real-world use

• Social anxiety disorder affects 30 million Americans, with prevalence rising post-pandemic.

• No approved acute treatments exist; current options are off-label and unsatisfactory.

• Product is consumer-oriented, with telehealth expected to drive access and recurring prescriptions.

• Multi-billion dollar peak potential projected, with modest pricing and utilization assumptions.